RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.